Corticosteroid Therapy Guidelines

Pharmacological Considerations

Dexamethasone is approximately 5 times more potent than methylprednisolone, with an equivalent dose of 10 mg dexamethasone comparable to 48 mg methylprednisolone, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 1

The American College of Clinical Oncology recommends dexamethasone for antiemetic regimens in high, moderate, and low emetic risk chemotherapy, with dosing on days 1-4, day 1 (or days 1-3), and day 1, respectively 2
In pediatric acute lymphoblastic leukemia, dexamethasone shows improved outcomes during induction in patients younger than 10 years of age, according to the National Comprehensive Cancer Network 3
However, dexamethasone is associated with a higher risk of osteonecrosis in patients 10 years or older, suggesting age should be considered when selecting a corticosteroid, as noted by the National Comprehensive Cancer Network 3, 4
For immune effector cell-associated neurotoxicity, the National Comprehensive Cancer Network recommends dexamethasone 10 mg IV for grade 2 neurotoxicity, and methylprednisolone 1 mg/kg IV for grade 3 neurotoxicity 5
In sudden sensorineural hearing loss, both corticosteroids are considered equivalent in safety and efficacy, but dexamethasone may yield better outcomes for intratympanic administration, as reported by the American Academy of Otolaryngology-Head and Neck Surgery 1, 6, 7

The American Academy of Otolaryngology-Head and Neck Surgery notes that prednisone 60 mg is equivalent to methylprednisolone 48 mg and dexamethasone 10 mg, and recommends single daily doses for both medications 2, 1
Both medications can be administered orally, intravenously, or intratympanically, depending on the clinical scenario, as stated by the American Academy of Otolaryngology-Head and Neck Surgery and the National Comprehensive Cancer Network 2, 1, 6
Underdosing and age considerations are common pitfalls, with the National Comprehensive Cancer Network noting that dexamethasone shows better outcomes in younger pediatric ALL patients but higher osteonecrosis risk in those over 10 years 1, 4

Dexamethasone is approximately 5 times more potent than methylprednisolone, with superior blood-brain barrier penetration and longer duration of action, making it preferred for CNS conditions and antiemetic prophylaxis, while methylprednisolone is preferred for acute severe inflammatory conditions requiring rapid high-dose IV therapy and IgE-mediated reactions 8
Dexamethasone is 25 times more potent than hydrocortisone, while methylprednisolone is only 5 times more potent than hydrocortisone 8
The equivalent anti-inflammatory doses are: dexamethasone 10 mg = methylprednisolone 48 mg = prednisone 60 mg 8

The American Society of Clinical Oncology recommends dexamethasone for antiemetic regimens across all emetic risk categories, given on days 1-4 for high-risk chemotherapy 9
For first-line treatment of immune thrombocytopenia (ITP), dexamethasone 40 mg daily for 4 days produces 86-90% initial response rates with 50-80% sustained responses lasting median 8 months 10, 11
High-dose methylprednisolone 30 mg/kg/day for 7 days achieves 95% response rates but only 23% sustained response at 39 months, typically requiring maintenance oral corticosteroids 10, 11

The methylprednisolone dose pack provides only the equivalent of 105 mg prednisone, compared to 540 mg prednisone over 14 days using standard dosing, representing significant underdosing 8
At biologically equivalent doses, oral formulations are equally effective as intravenous for both agents 9
Single daily doses are preferred for both medications 9, 8